Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor
This study adds irinotecan, temozolomide and bevacizumab to the chemotherapy regimen currently used to treat Desmoplastic small round cell tumor (DSRCT). The investigators are doing this study to find out what effects, good and/or bad, the combination of irinotecan, temozolomide and bevacizumab has on the patient and the DSRCT cancer.
Sarcoma|Desmoplastic Small Round Cell Tumor (DSRCT)
DRUG: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
To define the tolerability, of irinotecan, temozolomide and bevacizumab in patients with newly diagnosed DSRCT, 2 years|To define adverse event profile, of irinotecan, temozolomide and bevacizumab in patients with newly diagnosed DSRCT, 2 years
To estimate the response rate of two cycles of irinotecan, temozolomide and bevacizumab, In patients with measurable disease. added to the initial treatment of patients with Desmoplastic small round cell tumor (DSRCT), 2 years|To estimate survival, with the addition of irinotecan, temozolomide and bevacizumab to the initial treatment of patients with DSRCT, 2 years|To estimate time to progression, with the addition of irinotecan, temozolomide and bevacizumab to the initial treatment of patients with DSRCT, 2 years|To assess use of 18FDG PET-CT, as an early indicator of response in those patients with measurable or evaluable disease, 2 years
This study adds irinotecan, temozolomide and bevacizumab to the chemotherapy regimen currently used to treat Desmoplastic small round cell tumor (DSRCT). The investigators are doing this study to find out what effects, good and/or bad, the combination of irinotecan, temozolomide and bevacizumab has on the patient and the DSRCT cancer.